Lexicon shares baseline data from heart disease drug trial

Lexicon Pharmaceuticals (LXRX) reported preclinical data showing sotagliflozin improved cardiac function in mice and reduced platelet activation. The company expects Phase 3 SONATA-HCM topline results in Q1 2027. The data aims to support ongoing clinical development and differentiation from SGLT2-only drugs.

Lexicon Pharmaceuticals (LXRX) stock rose nearly 6% after Cantor Fitzgerald analyst Steve Seedhouse initiated coverage with an overweight rating and $8 price target, citing potential FDA approval for sotagliflozin in treating hypertrophic cardiomyopathy. The drug is currently in late-stage development for this indication, with Seedhouse noting its unique mechanism could complement existing treatments.

Lexicon Pharmaceuticals (LXRX) stock rose 10% after Cantor Fitzgerald initiated coverage with an Overweight rating and $8 price target. The bullish outlook is based on the company's Phase 3 SONATA-HCM trial for sotagliflozin, which has completed enrollment. The stock's surge contrasts with broader market declines, including a 1% drop in the Nasdaq.

Lexicon Pharmaceuticals (LXRX) shares rose 13% after Cantor Fitzgerald initiated coverage with an Overweight rating and $8.00 price target, citing potential in its HCM research. The firm believes sotagliflozin could succeed in Phase 3 trials and avoid competition, offering significant upside.

Lexicon Pharmaceuticals (LXRX) reported new Phase 3 data for sotagliflozin, showing consistent efficacy and safety across baseline systolic blood pressure in heart failure patients. The results were presented at ESC Congress 2026 and in JACC: Heart Failure. The company is unprofitable, with a net loss of $61.1 million in 2024, and relies on external funding. Analysts project $81.9 million in sales and $16.1 million in earnings by 2029, assuming 5.5% yearly revenue growth. The current share price

Lexicon (LXRX) discussed its Q2 2026 earnings call, focusing on sotagliflozin. The company said SONATA-HCM enrollment is complete and the trial was overenrolled, with top-line results expected in Q1 2027. For Zynquista, Lexicon said FDA resubmission criteria may be met after STENO1 reaches exposure targets by end of August, targeting an NDA resubmission in Q4 2026. It also noted Viatris regulatory progress for sotagliflozin and Novo Nordisk’s Phase I for 9851.